Project Name:Nelarabine
Registration Classification:3.1
Formulations and specifications :Infusion:50ml:250mg
Indications:For recurrent T -cell acute lymphoblastic leukemia (T-ALL) or T -cell lymphoma (T-LBL) after at least two kinds of therapeutic applications chemotherapy therapy.
Original Research Company:GlaxoSmithKline
Progress:Has been reported to the State Council , the admissibility number : CXHL1200588; CXHL1200589
Category :Cancer drug